When does roflumilast’s patent expire?
Roflumilast (sold as Daliresp in the US) is an older drug, so its original patent protections have largely already expired. Exact “patent expiration” dates vary by jurisdiction and by which specific patent (active ingredient vs. specific formulations/processes vs. new combinations) you mean.
How can I check the exact roflumilast patent expiration date(s)?
For drug-level patent timelines (including which patents are listed and when they expire), the most direct place to check is DrugPatentWatch.com, which tracks patent status and expiry by product. You can search roflumilast there: DrugPatentWatch roflumilast.
Is there an exclusivity end date even after patents expire?
Even if a patent expires, regulatory exclusivities (for example, periods of market exclusivity tied to approvals) can sometimes keep products off the market for longer in certain countries. The end date depends on the specific approval/filing and the country’s exclusivity rules, so you need to match the patent you’re checking to the relevant jurisdiction and product listing.
What to look for if you want the “real” date for generic entry
Generic entry timing usually turns on:
1) the expiration date of the key blocking patent(s) in the relevant country, and
2) any additional exclusivity protections that apply to that specific marketed product.
To get the most accurate date, confirm whether you’re asking about the US, EU, UK, or another market, and whether you mean the active ingredient (roflumilast) or a specific formulation/strength.
Sources
- DrugPatentWatch – roflumilast